No Data
Is Nanjing Vazyme Biotech (SHSE:688105) Using Debt Sensibly?
Nuo Weizan (688105.SH) plans to distribute 0.3 yuan for every 10 shares in the first three quarters, with ex-dividend and ex-rights date on December 20.
Nuoweizan (688105.SH) announced that the company plans to distribute... for every 10 shares to all Shareholders in the first three quarters of 2024.
Nuo Weizan (688105.SH): plans to use 0.221 billion yuan of oversubscribed funds to permanently supplement working capital.
On December 12, Gelonghui reported that Nuo Wei Zan (688105.SH) announced that it intends to change the use of the unused raised funds for the "Phase I Project of the Production Base Project" to permanently supplement its working capital, which will be used for the company's daily Operation and Business development. The company will subsequently use its own funds to timely advance the construction of the "Phase I Project of the Production Base Project" based on the development of the external market. The amount of raised funds intended for permanent working capital supplementation is 221.4479 million yuan, accounting for 24.41% of the total raised funds.
Private Companies Among Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 12% Last Week
Norwalk (688105.SH): Cumulatively repurchased 1.08% of the company's shares.
On November 1, GeLonghui reported that as of October 31, 2024, Nouweizan (688105.SH) announced that the company repurchased a total of 4,301,724 shares of the company through the Shanghai Stock Exchange system through centralized auction trading, accounting for 1.08% of the total share capital of 400,010,000 shares. The lowest price for repurchase transactions was 17.65 yuan/share and the highest price was 28.65 yuan/share. The total payment amount was 104,011,578.16 yuan (excluding transaction costs).
Novi Zam: third quarter report 2024
Investors Don't See Light At End Of Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Tunnel And Push Stock Down 27%
No Data
